N. I have been going over this with poster HamPanky ...chk his posts re Teva .
I've been arguing that Teva already has an established " fish oil " API and sales structure in place ...selling generic Lovaza. His DD has revealed several others in the G Lovaza space ..O3 Ethyl Esters .
Teva already has a royalty payment arrangement with AMRN via their settlement agreement . If AMRN was to lose the appeal trial I surmise it would be in Amarins interest to assign its API supply agreements to Teva ...because at least they still get the royalty payment .
Rather than having a fragmented market between several generic Co's ...AMRN would help Teva dominate ..and get royalties . Just looking at all possibilities ...still want AMRN to win the appeal obviously
Market Data 
Markets 
